The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

Objective This study aims to evaluate the correlation between viral clearance and blood biochemical index of 94 discharged patients with COVID-19 infection in Shenzhen Third People’s Hospital, enrolled from Jan 5 to Feb 13, 2020. Methods The clinical and laboratory findings were extracted from the e...

Full description

Saved in:
Bibliographic Details
Published in:Inflammation research 2020-06, Vol.69 (6), p.599-606
Main Authors: Yuan, Jing, Zou, Rougrong, Zeng, Lijiao, Kou, Shanglong, Lan, Jianfeng, Li, Xiaohe, Liang, Yanhua, Ding, Xiaoyan, Tan, Guoyu, Tang, Shenghong, Liu, Lei, Liu, Yingxia, Pan, Yanchao, Wang, Zhaoqin
Format: Article
Language:eng
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study aims to evaluate the correlation between viral clearance and blood biochemical index of 94 discharged patients with COVID-19 infection in Shenzhen Third People’s Hospital, enrolled from Jan 5 to Feb 13, 2020. Methods The clinical and laboratory findings were extracted from the electronic medical records of the patients. The data were analysed and reviewed by a trained team of physicians. Information on clinical signs and symptoms, medical treatment, virus clearance, and laboratory parameters including interleukin 6 (IL-6) and C-reactive protein were collected. Results COVID-19 mRNA clearance ratio was identified significantly correlated with the decline of serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels. Furthermore, COVID-19 mRNA clearance time was positively correlated with the length of hospital stay in patients treated with either IFN-α + lopinavir/ritonavir or IFN-α + lopinavir/ritonavir + ribavirin. Conclusions Therapeutic regimens of IFN-α + lopinavir/ritonavir and IFN-α + lopinavir/ritonavir + ribavirin might be beneficial for treatment of COVID-19. Serum LDH or CK decline may predict a favorable response to treatment of COVID-19 infection.
ISSN:1023-3830
1420-908X